Skip to main content
Top
Published in: Advances in Therapy 11/2014

01-11-2014 | Original Research

Clinical Usefulness of Diquafosol for Real-World Dry Eye Patients: A Prospective, Open-Label, Non-Interventional, Observational Study

Authors: Masahiko Yamaguchi, Takeshi Nishijima, Jun Shimazaki, Etsuko Takamura, Norihiko Yokoi, Hitoshi Watanabe, Yuichi Ohashi

Published in: Advances in Therapy | Issue 11/2014

Login to get access

Abstract

Introduction

This study was designed to evaluate the efficacy and safety of 3% diquafosol ophthalmic solution in dry eye patients in clinical practice.

Methods

Subjects were dry eye patients who had never used diquafosol, and observation was conducted prospectively over 2 months. The corneal and conjunctival fluorescein staining score, tear film break-up time, 12 dry eye-related subjective symptoms, patient-reported outcomes, and adverse events were investigated.

Results

Data were collected from 465 medical institutions for 3,196 patients. Diquafosol led to significant improvement in all subjective symptoms and objective findings (P < 0.001, paired t test). Diquafosol was effective regardless of the degree of severity according to the corneal and conjunctival fluorescein staining score or therapeutic pattern. Overall, 76.0% patients responded that their condition had improved. Adverse reactions were observed in 6.3% of patients. The major adverse reactions were eye discharge, eye irritation, and eye pain.

Conclusion

Diquafosol was effective for various dry eye patients in clinical practice, and no significant safety-related problems occurred.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shimazaki J. Dry Eye Research Group. Diagnostic criteria of dry eye 2006 [in Japanese]. Atarashii Ganaka (J Eye). 2007;24:181–4. Shimazaki J. Dry Eye Research Group. Diagnostic criteria of dry eye 2006 [in Japanese]. Atarashii Ganaka (J Eye). 2007;24:181–4.
2.
go back to reference The Definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of International Dry Eye Work Shop. Ocul Surf. 2007;5:75–92. The Definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of International Dry Eye Work Shop. Ocul Surf. 2007;5:75–92.
3.
go back to reference Uchino M, Schaumberg DA, Dogru M, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008;115:1982–8.PubMedCrossRef Uchino M, Schaumberg DA, Dogru M, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008;115:1982–8.PubMedCrossRef
4.
go back to reference Albietz JM. Prevalence of dry eye subtypes in clinical optometry practice. Optom Vis Sci. 2000;77:357–63.PubMedCrossRef Albietz JM. Prevalence of dry eye subtypes in clinical optometry practice. Optom Vis Sci. 2000;77:357–63.PubMedCrossRef
5.
go back to reference Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.PubMedCrossRef Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.PubMedCrossRef
6.
go back to reference Murakami T, Fujihara T, Nakamura M, Nakata K. P2Y(2) receptor elicits PAS-positive glycoprotein secretion from rabbit conjunctival goblet cells in vivo. J Ocul Pharmacol Ther. 2003;19:345–52.PubMedCrossRef Murakami T, Fujihara T, Nakamura M, Nakata K. P2Y(2) receptor elicits PAS-positive glycoprotein secretion from rabbit conjunctival goblet cells in vivo. J Ocul Pharmacol Ther. 2003;19:345–52.PubMedCrossRef
7.
go back to reference Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77:77–84.PubMedCrossRef Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77:77–84.PubMedCrossRef
8.
go back to reference Hosoya K, Ueda H, Kim K, Lee VHL. Nucleotide stimulation of Cl− secretion in the pigmented rabbit conjunctiva. J Pharmacol Exp Ther. 1999;291:53–9.PubMed Hosoya K, Ueda H, Kim K, Lee VHL. Nucleotide stimulation of Cl secretion in the pigmented rabbit conjunctiva. J Pharmacol Exp Ther. 1999;291:53–9.PubMed
9.
go back to reference Li Y, Kuang K, Yerxa B, Quan W, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl− and fluid secretion. Am J Physiol Cell Physiol. 2001;281:C595–602.PubMed Li Y, Kuang K, Yerxa B, Quan W, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl and fluid secretion. Am J Physiol Cell Physiol. 2001;281:C595–602.PubMed
10.
go back to reference Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.PubMedCrossRef Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.PubMedCrossRef
11.
go back to reference Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.PubMedCrossRef Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.PubMedCrossRef
12.
go back to reference Takamura E, Tsubota K, Watanabe H, Ohashi Y. Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomized, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.PubMedCentralPubMedCrossRef Takamura E, Tsubota K, Watanabe H, Ohashi Y. Diquafosol Ophthalmic Solution Phase 3 Study Group. A randomized, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.PubMedCentralPubMedCrossRef
13.
go back to reference Yamaguchi M, Tsubota K, Watanabe H, Ohashi Y. The safety and efficacy of long-term treatment with 3% diquafosol ophthalmic solution for dry eye [in Japanese]. Atarashii Ganaka (J Eye). 2012;29:527–35. Yamaguchi M, Tsubota K, Watanabe H, Ohashi Y. The safety and efficacy of long-term treatment with 3% diquafosol ophthalmic solution for dry eye [in Japanese]. Atarashii Ganaka (J Eye). 2012;29:527–35.
14.
go back to reference Koh S, Watanabe H, Hosohata J, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.PubMedCrossRef Koh S, Watanabe H, Hosohata J, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.PubMedCrossRef
15.
16.
go back to reference Nakamura M, Mishima H, Nishida T, Otori T. Binding of hyaluronan to plasma fibronectin increases the attachment of corneal epithelial cells to a fibronectin matrix. J Cell Physiol. 1994;159:415–22.PubMedCrossRef Nakamura M, Mishima H, Nishida T, Otori T. Binding of hyaluronan to plasma fibronectin increases the attachment of corneal epithelial cells to a fibronectin matrix. J Cell Physiol. 1994;159:415–22.PubMedCrossRef
17.
go back to reference Nakamura M, Nishida T, Hikida M, Otori T. Combined effects of hyaluronan and fibronectin on corneal epithelial wound closure of rabbit in vivo. Curr Eye Res. 1994;13:385–8.PubMedCrossRef Nakamura M, Nishida T, Hikida M, Otori T. Combined effects of hyaluronan and fibronectin on corneal epithelial wound closure of rabbit in vivo. Curr Eye Res. 1994;13:385–8.PubMedCrossRef
18.
go back to reference Nakamura M, Hikida M, Nakano T, Ito S, Hamano T, Kinoshita S. Characterization of water retentive properties of hyaluronan. Cornea. 1993;12:433–6.PubMedCrossRef Nakamura M, Hikida M, Nakano T, Ito S, Hamano T, Kinoshita S. Characterization of water retentive properties of hyaluronan. Cornea. 1993;12:433–6.PubMedCrossRef
19.
go back to reference Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol. 2014;157:85–92.PubMedCrossRef Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol. 2014;157:85–92.PubMedCrossRef
20.
go back to reference Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32:1120–5.PubMedCrossRef Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32:1120–5.PubMedCrossRef
21.
go back to reference Management and therapy of dry eye disease: report of the management and therapy of the international dry eye workshop (2007). Ocul Surf. 2007;5:163–178. Management and therapy of dry eye disease: report of the management and therapy of the international dry eye workshop (2007). Ocul Surf. 2007;5:163–178.
22.
go back to reference Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology. 1993;100:347–51.PubMedCrossRef Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology. 1993;100:347–51.PubMedCrossRef
23.
go back to reference Paranjpe DR, Foulks GN. Therapy for meibomian gland disease. Ophthalmol Clin North Am. 2003;16:37–42.PubMedCrossRef Paranjpe DR, Foulks GN. Therapy for meibomian gland disease. Ophthalmol Clin North Am. 2003;16:37–42.PubMedCrossRef
24.
go back to reference Arita R, Suehiro J, Haraguchi T, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725–9.PubMedCentralPubMedCrossRef Arita R, Suehiro J, Haraguchi T, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725–9.PubMedCentralPubMedCrossRef
25.
go back to reference Sakane Y, Yamaguchi M, Yokoi N, et al. Development and validation of dry eye-related quality-of-life score questionnaire. JAMA Opthalmol. 2013;131:1331–8.CrossRef Sakane Y, Yamaguchi M, Yokoi N, et al. Development and validation of dry eye-related quality-of-life score questionnaire. JAMA Opthalmol. 2013;131:1331–8.CrossRef
Metadata
Title
Clinical Usefulness of Diquafosol for Real-World Dry Eye Patients: A Prospective, Open-Label, Non-Interventional, Observational Study
Authors
Masahiko Yamaguchi
Takeshi Nishijima
Jun Shimazaki
Etsuko Takamura
Norihiko Yokoi
Hitoshi Watanabe
Yuichi Ohashi
Publication date
01-11-2014
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 11/2014
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-014-0162-4

Other articles of this Issue 11/2014

Advances in Therapy 11/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine